Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.71 | 0.34 | -0.38 | -0.00 |
| FCF Yield | 3.29% | 2.26% | -0.42% | 3.87% |
| EV / EBITDA | 50.41 | 28.48 | 33.17 | 43.89 |
| Quality | ||||
| ROIC | 0.01% | 2.89% | 2.51% | 3.78% |
| Gross Margin | 34.92% | 39.51% | 36.80% | 35.98% |
| Cash Conversion Ratio | 6.53 | 2.35 | 0.30 | -5.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.14% | 7.26% | 7.59% | 8.09% |
| Free Cash Flow Growth | 80.40% | 625.17% | -111.49% | -21.52% |
| Safety | ||||
| Net Debt / EBITDA | 22.25 | 14.13 | 16.30 | 22.07 |
| Interest Coverage | -0.00 | 1.71 | 1.76 | 1.23 |
| Efficiency | ||||
| Inventory Turnover | 0.83 | 0.72 | 0.73 | 0.76 |
| Cash Conversion Cycle | 80.87 | 93.62 | 187.30 | 167.70 |